Form D · Biotechnology
SVELTE MEDICAL SYSTEMS INC
New Providence, NJ · CIK 0001396555
Offering snapshot reported May 6, 2021 · SEC filing
- Reported sold
- $5.45M Offering amount: $10.8M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 6, 2021 | Initial | $5,445,363 | No comparison | Not reported | SEC filing |
| Nov 21, 2017 | Initial | $3,000,000 | No comparison | 10 | SEC filing |
| Jul 10, 2017 | Amendment | $12,300,000 | $8,300,000vs Jul 27, 2016 | 9 | SEC filing |
| Jul 27, 2016 | Amendment | $50,402,467 | $6,000,000vs Feb 22, 2016 | 39 | SEC filing |
| Jul 27, 2016 | Initial | $4,000,000 | No comparison | 4 | SEC filing |
| Feb 22, 2016 | Amendment | $44,402,467 | $6,394,143vs Mar 18, 2015 | 37 | SEC filing |
| Mar 18, 2015 | Amendment | $38,008,324 | $11,372,000vs Mar 12, 2014 | 30 | SEC filing |
| Mar 12, 2014 | Amendment | $26,636,324 | $8,704,970vs Nov 8, 2013 | 27 | SEC filing |
| Nov 8, 2013 | Initial | $17,931,354 | No comparison | 26 | SEC filing |
| Jun 4, 2013 | Amendment | $4,307,884 | $2,498,329vs Apr 29, 2013 | 7 | SEC filing |
| Apr 29, 2013 | Initial | $1,809,555 | No comparison | 3 | SEC filing |
| Jun 21, 2012 | Initial | $5,000,000 | No comparison | 13 | SEC filing |
| Dec 14, 2011 | Initial | $18,784,666 | No comparison | 22 | SEC filing |
| Jul 15, 2011 | Amendment | $9,694,400 | $5,201,700vs Oct 27, 2010 | 22 | SEC filing |
| Oct 27, 2010 | Initial | $4,492,700 | No comparison | 14 | SEC filing |
| Mar 16, 2010 | Amendment | $4,151,043 | -$1,848,957vs Nov 27, 2009 | 22 | SEC filing |
| Nov 27, 2009 | Initial | $6,000,000 | No comparison | 11 | SEC filing |
| May 28, 2009 | Amendment | $6,270,000 | No comparison | Not reported | SEC filing |
| Feb 12, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Apr 25, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Apr 11, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-398487
Source: Form D, filed May 6, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dan Bowen | Director |
| Janet Burpee | Executive |
| Steve Burpee | Director |
| Michael Caponetto | Director |
| Robert Croce | Director, Executive |
| Richard Dakers | Director |
| Jack Darby | Director, Executive |
| Fernando Di Caprio | Director, Executive |
| Robert E. Fischell | Director, Executive |
| David R. Fischell | Director |
| Tim A. Fischell | Executive |
| Robert Flanagan | Director |
| Michael Johnson | Executive |
| Mark A. Kielek | Executive |
| Timothy Lash | Director |
| Mark Pomeranz | Executive |
| Joseph Smith | Director |
| Mina Sooch | Director |
| Richard T. Spencer | Executive |
| Somu Subramaniam | Director |
| Phillip D. Torrence | Executive |
| Nicholas Valeriani | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
675 Central Avenue Suite 2
New Providence, NJ, 07974
New Providence, NJ, 07974